Literature DB >> 16117801

Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes.

Julie Lang1, Rona M MacKie.   

Abstract

DNA was extracted from 52 thick primary melanomas and mutations sought in exon 15 of the BRAF (v-raf murine sarcoma viral oncogene homolog B1) gene using denaturing high performance liquid chromatograph (dHPLC) fragment analysis, sequencing, and allele-specific PCR. Exon 15 BRAF mutations were found in 13 of 52 (25%) primary melanomas. These comprised five of 17 (29%) superficial spreading melanomas, three of 11 (27%) nodular melanomas, two of 13 (15%) acral lentiginous melanomas, one of one (100%) mucosal melanoma and two of 10 (20%) lentigo maligna melanomas. In common with other groups, our findings show a relative concentration of the exon 15 BRAF mutation in superficial spreading and nodular melanomas, but add further evidence that this mutation not necessary for malignant transformation of the melanocyte.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16117801     DOI: 10.1111/j.0022-202X.2005.23833.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  18 in total

Review 1.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

Review 2.  Therapeutic targets in melanoma: map kinase pathway.

Authors:  Frank G Haluska; Nageatte Ibrahim
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

3.  The BRAF V600K mutation is more frequent than the BRAF V600E mutation in melanoma in situ of lentigo maligna type.

Authors:  Elke Stadelmeyer; Ellen Heitzer; Margit Resel; Lorenzo Cerroni; Peter Wolf; Nadia Dandachi
Journal:  J Invest Dermatol       Date:  2013-08-09       Impact factor: 8.551

4.  Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

Authors:  Carol Beadling; Michael C Heinrich; Andrea Warrick; Erin M Forbes; Dylan Nelson; Emily Justusson; Judith Levine; Tanaya L Neff; Janice Patterson; Ajia Presnell; Arin McKinley; Laura J Winter; Christie Dewey; Amy Harlow; Oscar Barney; Brian J Druker; Kathryn G Schuff; Christopher L Corless
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

Review 5.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin.

Authors:  David C Whiteman; William J Pavan; Boris C Bastian
Journal:  Pigment Cell Melanoma Res       Date:  2011-08-16       Impact factor: 4.693

Review 6.  Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.

Authors:  Holly S Greenwald; Erica B Friedman; Iman Osman
Journal:  Melanoma Res       Date:  2012-02       Impact factor: 3.599

7.  Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.

Authors:  Marina Kvaskoff; David C Whiteman; Zhen Z Zhao; Grant W Montgomery; Nicholas G Martin; Nicholas K Hayward; David L Duffy
Journal:  Twin Res Hum Genet       Date:  2011-10       Impact factor: 1.587

8.  Shedding of distinct cryptic collagen epitope (HU177) in sera of melanoma patients.

Authors:  Bruce Ng; Jan Zakrzewski; Melanie Warycha; Paul J Christos; Dean F Bajorin; Richard L Shapiro; Russell S Berman; Anna C Pavlick; David Polsky; Madhu Mazumdar; Anthony Montgomery; Leonard Liebes; Peter C Brooks; Iman Osman
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

9.  Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site.

Authors:  Anton Platz; Suzanne Egyhazi; Ulrik Ringborg; Johan Hansson
Journal:  Mol Oncol       Date:  2007-12-28       Impact factor: 6.603

10.  [Molecular heterogeneity of malignant melanomas].

Authors:  K Glatz
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.